CLDX
Price
$16.84
Change
+$0.90 (+5.65%)
Updated
Apr 11 closing price
Capitalization
1.12B
19 days until earnings call
DNLI
Price
$12.70
Change
+$0.20 (+1.60%)
Updated
Apr 11 closing price
Capitalization
1.84B
31 days until earnings call
Ad is loading...

CLDX vs DNLI

Header iconCLDX vs DNLI Comparison
Open Charts CLDX vs DNLIBanner chart's image
Celldex Therapeutics
Price$16.84
Change+$0.90 (+5.65%)
Volume$805.58K
Capitalization1.12B
Denali Therapeutics
Price$12.70
Change+$0.20 (+1.60%)
Volume$1.63M
Capitalization1.84B
CLDX vs DNLI Comparison Chart
Loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLDX vs. DNLI commentary
Apr 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and DNLI is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 12, 2025
Stock price -- (CLDX: $16.84 vs. DNLI: $12.70)
Brand notoriety: CLDX and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 99% vs. DNLI: 119%
Market capitalization -- CLDX: $1.12B vs. DNLI: $1.84B
CLDX [@Biotechnology] is valued at $1.12B. DNLI’s [@Biotechnology] market capitalization is $1.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 3 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • CLDX’s TA Score: 3 bullish, 4 bearish.
  • DNLI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than CLDX.

Price Growth

CLDX (@Biotechnology) experienced а +6.72% price change this week, while DNLI (@Biotechnology) price change was +7.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.15%. For the same industry, the average monthly price growth was -16.20%, and the average quarterly price growth was -17.21%.

Reported Earning Dates

CLDX is expected to report earnings on Aug 07, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+0.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.84B) has a higher market cap than CLDX($1.12B). CLDX YTD gains are higher at: -33.360 vs. DNLI (-37.684). CLDX has higher annual earnings (EBITDA): -191.9M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. CLDX (725M). CLDX has less debt than DNLI: CLDX (3.81M) vs DNLI (48.7M). CLDX has higher revenues than DNLI: CLDX (7.02M) vs DNLI (0).
CLDXDNLICLDX / DNLI
Capitalization1.12B1.84B61%
EBITDA-191.9M-492.89M39%
Gain YTD-33.360-37.68489%
P/E RatioN/AN/A-
Revenue7.02M0-
Total Cash725M832M87%
Total Debt3.81M48.7M8%
FUNDAMENTALS RATINGS
CLDX vs DNLI: Fundamental Ratings
CLDX
DNLI
OUTLOOK RATING
1..100
5360
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
94
Overvalued
PROFIT vs RISK RATING
1..100
65100
SMR RATING
1..100
9338
PRICE GROWTH RATING
1..100
9189
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (58) in the Biotechnology industry is somewhat better than the same rating for DNLI (94). This means that CLDX’s stock grew somewhat faster than DNLI’s over the last 12 months.

CLDX's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for DNLI (100). This means that CLDX’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's SMR Rating (38) in the Biotechnology industry is somewhat better than the same rating for CLDX (93). This means that DNLI’s stock grew somewhat faster than CLDX’s over the last 12 months.

DNLI's Price Growth Rating (89) in the Biotechnology industry is in the same range as CLDX (91). This means that DNLI’s stock grew similarly to CLDX’s over the last 12 months.

DNLI's P/E Growth Rating (97) in the Biotechnology industry is in the same range as CLDX (100). This means that DNLI’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXDNLI
RSI
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
N/A
Bullish Trend 16 days ago
79%
Declines
ODDS (%)
Bearish Trend 5 days ago
80%
Bearish Trend 5 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
75%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSCIX35.62N/A
N/A
abrdn US Small Cap Equity Inst
JSCRX16.30N/A
N/A
PGIM Jennison Small Company R
LYRAX23.57N/A
N/A
Lyrical US Value Equity A
PREIX138.55N/A
N/A
T. Rowe Price Equity Index 500
BFIIX16.17N/A
N/A
Baron FinTech Institutional

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with DNLI. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+5.65%
DNLI - CLDX
51%
Loosely correlated
+1.60%
KYMR - CLDX
49%
Loosely correlated
+7.68%
BEAM - CLDX
48%
Loosely correlated
+5.74%
ATXS - CLDX
46%
Loosely correlated
-0.49%
NUVB - CLDX
46%
Loosely correlated
+13.71%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RCKT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+1.60%
RCKT - DNLI
60%
Loosely correlated
+6.68%
BEAM - DNLI
58%
Loosely correlated
+5.74%
NTLA - DNLI
56%
Loosely correlated
+9.45%
CRSP - DNLI
54%
Loosely correlated
+14.71%
RGNX - DNLI
54%
Loosely correlated
+8.87%
More